Company profile: Navamedic
1.1 - Company Overview
Company description
- Provider of pharmaceutical and medtech products, marketing to patients, hospitals and pharmacies. Offers prescription and OTC medicines and healthcare products; the Sippi next-generation digital urine meter; and a portfolio including Eroxon gel to help men achieve an erection, Flexilev for Parkinson’s, Absolut Torr antiperspirant, MedMade micronutrient supplements, and PKU and obesity education/support programs.
Products and services
- Eroxon: Clinically proven gel that helps men achieve an erection within 10 minutes, delivering time-bound efficacy for erectile support
- Flexilev: Personalized treatment for Parkinson’s Disease, supporting individualized patient management with a patient-tailored therapeutic approach designed around personal needs
- Absolut Torr: Long-lasting antiperspirant for people with hyperhidrosis, supplying extended sweat reduction and durable protection for individuals experiencing excessive perspiration
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Navamedic
G7 Therapeutics
HQ: Switzerland
Website
- Description: Provider of proprietary approaches to stabilize G protein-coupled receptors (GPCRs), enabling novel structure-based drug development for designing highly selective small molecules or biologics targeting GPCRs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full G7 Therapeutics company profile →
Arch Biopartners
HQ: Canada
Website
- Description: Provider of product acquisition and development for sale to pharmaceutical and industrial companies, with a focus on LSALT peptide (Metablok), a drug candidate that inhibits DPEP1 to target acute organ inflammation in the lungs, liver, and kidneys, including a Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide for cardiac surgery–associated acute kidney injury.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arch Biopartners company profile →
Plexxikon
HQ: United States
Website
- Description: Provider of small molecule pharmaceuticals focused on discovering and developing therapies for human diseases. Portfolio includes Zelboraf for BRAF V600E–mutant skin cancer, Turalio for tenosynovial giant cell tumor (TGCT), and personalized medicines. Pipeline candidates include PLX204 for diabetes, PLX4032 for melanoma and colorectal cancer, and PLX5568 kinase inhibitors for pain and polycystic kidney disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Plexxikon company profile →
Palatin Technologies
HQ: United States
Website
- Description: Provider of targeted receptor-specific peptide therapeutics, including Vyleesi (bremelanotide injection) for premenopausal women with HSDD, and a pipeline of melanocortin-based candidates: PL9643 (Phase 3) for dry eye disease; PL9654 for ocular diseases (IVT and topical); PL8177 (oral, Phase 2) for ulcerative colitis; bremelanotide + PDE5i (Phase 2) for sexual dysfunction; and a planned MCR4 agonist program for obesity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palatin Technologies company profile →
Rexahn Pharmaceuticals
HQ: United States
Website
- Description: Provider of treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rexahn Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Navamedic
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Navamedic
2.2 - Growth funds investing in similar companies to Navamedic
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Navamedic
4.2 - Public trading comparable groups for Navamedic
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →